A record of what HSBC Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“HSBC maintains a 'buy' rating on Biocon shares, following a significant boost from a ₹4,500 crore Qualified Institutional Placement (QIP). The QIP is expected to strengthen the company's financial position and support future growth initiatives, leading to a positive outlook for the stock.”
HSBC Analysis’s track record (trackable calls only): 34 graded calls · 95% CI 31–63%
BioconBullishCalled 19 Jun 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee HSBC Analysis’s full track record